Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04030338 · ClinicalTrials.gov registry record
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
A clinical trial of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 58
- Enrollment target
- 7
- Study locations
NCT04030338: Active study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04030338 is a study of Prostate Cancer and Prostate Adenocarcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 58 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04030338, a study of Prostate Cancer and Prostate Adenocarcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 58 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) scans used in this study accurate and better at imaging participants' prostate cancer than the usual methods.
Conditions Studied
Interventions
- DRUG 18F-DCFPyL-iPSMA
- DRUG 68Ga-HBED-iPSMA
- DIAGNOSTIC_TEST PET/CT scan
Study Locations (7)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2019-07-19 |
| Est. Completion | 2026-07 |
What the registry record for NCT04030338 still lists
NCT04030338 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower).
The record links to 5 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which 18F-DCFPyL-iPSMA is the first listed.
NCT04030338 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04030338 about?
NCT04030338 is a clinical study titled "Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer". The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) scans used in this study accurate and better at imaging participants' prostate cancer than the usual methods.
What is the current status of trial NCT04030338?
This trial is currently active not recruiting. The enrollment target is 58 participants. The study started on 2019-07-19. Estimated completion is 2026-07.
What conditions does trial NCT04030338 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma, Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Neoplasm.
What interventions are being tested in trial NCT04030338?
The interventions under investigation include: 18F-DCFPyL-iPSMA (DRUG), 68Ga-HBED-iPSMA (DRUG), PET/CT scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04030338?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04030338 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04030338's enrollment target sits among peer trials
58 447th of 735 higher than 285 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI